Inclusion Criteria:  Physician confirmed diagnosis of atopic dermatitis (AD) or atopic eczema at baseline. Symptom onset >=1-year prior to baseline. Initiation of upadacitinib treatment for AD is indicated and prescribed per local label. The decision to prescribe UPA is made prior to and independently of study participation. Medical and medication history available for previous 6 months. Participants who can understand the questionnaires, with parental support as required for adolescents. Participants who are able to understand and communicate with the investigator and comply with the requirements of the study. Participants who are willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., tablet). Participants who are willing and able to complete the patient-reported questionnaires.  Exclusion Criteria:  - Participants who are currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation).